KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Assets (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Assets for 6 consecutive years, with $1.4 billion as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Assets fell 2.64% year-over-year to $1.4 billion, compared with a TTM value of $1.4 billion through Sep 2025, down 2.64%, and an annual FY2024 reading of $1.4 billion, down 8.57% over the prior year.
  • Assets was $1.4 billion for Q3 2025 at AbCellera Biologics, down from $1.4 billion in the prior quarter.
  • Across five years, Assets topped out at $1.6 billion in Q2 2022 and bottomed at $1.1 billion in Q1 2021.
  • Average Assets over 5 years is $1.4 billion, with a median of $1.4 billion recorded in 2024.
  • The sharpest move saw Assets soared 41.09% in 2022, then fell 8.57% in 2024.
  • Year by year, Assets stood at $1.3 billion in 2021, then grew by 16.86% to $1.5 billion in 2022, then decreased by 3.43% to $1.5 billion in 2023, then dropped by 8.57% to $1.4 billion in 2024, then decreased by 0.34% to $1.4 billion in 2025.
  • Business Quant data shows Assets for ABCL at $1.4 billion in Q3 2025, $1.4 billion in Q2 2025, and $1.3 billion in Q1 2025.